{"id":"len-tace","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hepatic impairment"}]},"_chembl":{"chemblId":"CHEMBL213425","moleculeType":"Small molecule","molecularWeight":"367.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lenvatinib inhibits multiple receptor tyrosine kinases (FGFR, VEGFR, RET, KIT) to suppress tumor angiogenesis and growth signaling. When combined with TACE—a minimally invasive procedure delivering chemotherapy directly to the tumor via hepatic artery embolization—the approach provides both systemic kinase inhibition and concentrated local chemotherapy, potentially improving efficacy in hepatocellular carcinoma.","oneSentence":"Len-TACE combines lenvatinib (a multi-kinase inhibitor) with transarterial chemoembolization (TACE) to target hepatocellular carcinoma through dual mechanisms of kinase inhibition and localized chemotherapy delivery.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:18:28.710Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (HCC), unresectable or advanced"}]},"trialDetails":[{"nctId":"NCT07480382","phase":"NA","title":"Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC","status":"NOT_YET_RECRUITING","sponsor":"Hong Wu","startDate":"2026-04-01","conditions":"Initially Unresectable Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT06904196","phase":"PHASE2","title":"Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-04-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":78},{"nctId":"NCT06904183","phase":"PHASE2","title":"Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-04-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":320},{"nctId":"NCT06492395","phase":"PHASE3","title":"Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-08-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":178},{"nctId":"NCT05717738","phase":"","title":"Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2022-01-20","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT05738616","phase":"PHASE3","title":"Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)","status":"RECRUITING","sponsor":"Wen Tianfu","startDate":"2024-05-10","conditions":"Advanced Hepatocellular Carcinoma","enrollment":196},{"nctId":"NCT06265883","phase":"","title":"Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2019-07-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":205},{"nctId":"NCT06194695","phase":"","title":"DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Ze-yang Ding, MD","startDate":"2022-02-01","conditions":"Cholangiocarcinoma Non-resectable","enrollment":100},{"nctId":"NCT06192784","phase":"PHASE2","title":"Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2023-12-09","conditions":"Cholangiocarcinoma Non-resectable","enrollment":36},{"nctId":"NCT05985798","phase":"PHASE3","title":"Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2023-08-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":258},{"nctId":"NCT05608200","phase":"PHASE3","title":"Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2022-11-02","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":427},{"nctId":"NCT04967495","phase":"NA","title":"TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2021-07-09","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":171},{"nctId":"NCT04599790","phase":"PHASE2","title":"TACE Combined With Lenvatinib and Sintilimab for Advanced HCC","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2020-10-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":30},{"nctId":"NCT05608213","phase":"PHASE3","title":"Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2022-11-02","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":187},{"nctId":"NCT04974281","phase":"EARLY_PHASE1","title":"PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-01-01","conditions":"Hepatocellular Carcinoma","enrollment":50},{"nctId":"NCT02971345","phase":"PHASE3","title":"Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2017-01","conditions":"Hepatocellular Carcinoma, Portal Vein Tumor Thrombus","enrollment":253}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Len-TACE","genericName":"Len-TACE","companyName":"Second Affiliated Hospital of Guangzhou Medical University","companyId":"second-affiliated-hospital-of-guangzhou-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Len-TACE combines lenvatinib (a multi-kinase inhibitor) with transarterial chemoembolization (TACE) to target hepatocellular carcinoma through dual mechanisms of kinase inhibition and localized chemotherapy delivery. Used for Hepatocellular carcinoma (HCC), unresectable or advanced.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}